1. 1945 Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival according to body weight and anti-drug antibody status. (September 2015) Authors: Jackisch, C.; Hegg, R.; Stroyakovskiy, D.; Ahn, J.S.; Melichar, B.; Chen, S.C.; Crepelle-Fléchais, A.; Lauer, S.; Shing, M.; Pivot, X. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S313 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1956 Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses. (September 2015) Authors: Jung, K.H.; Ataseven, B.; Verrill, M.; De Laurentiis, M.; Azim, H.A.; Pivot, X.; Al-Sakaff, N.; Lauer, S.; Shing, M.; Gligorov, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P201 Subcutaneous versus intravenous trastuzumab in early breast cancer: 2-year follow-up of HannaH. (March 2015) Authors: Jackisch, C.; Hegg, R.; Stroyakovskiy, D.; Ahn, J.; Melichar, B.; Chen, S.C.; Crepelle-Flechais, A.; Heinzmann, D.; Shing, M.; Pivot, X. Journal: Breast Issue: Volume 24(2015)Supplement 1 Page Start: S94 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P103 Subcutaneous trastuzumab plus chemotherapy for early breast cancer: interim safety from SafeHer. (March 2015) Authors: Gligorov, J.; De Laurentiis, M.; Verrill, M.; Jung, K.H.; Azim, H.A.; Ataseven, B.; Al-Sakaff, N.; Heinzmann, D.; Shing, M.; Pivot, X. Journal: Breast Issue: Volume 24(2015)Supplement 1 Page Start: S60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. (September 2017) Authors: Gligorov, J.; Ataseven, B.; Verrill, M.; De Laurentiis, M.; Jung, K.H.; Azim, H.A.; Al-Sakaff, N.; Lauer, S.; Shing, M.; Pivot, X. Journal: European journal of cancer Issue: Volume 82(2017) Page Start: 237 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗